BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study GlobeNewswire July 31, 2025 PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the […]

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

(NASDAQ:DYAI), JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

(NASDAQ:RGEN), WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

(NASDAQ:IFRX), JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx

Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

(NASDAQ:PBM), NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety

MariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT Holdings

(Other OTC:MRMD),(OTC US:MRMD),(CNSX:MRMD.CN),(CNSX:MRMD),(CBOE:TILT.NE),(PinkSheets:TLLTF), NORWOOD, Mass., July 31, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced a strategic agreement with TILT Holdings (“TILT”) (CBOE: TILT) (OTCPK: TLLTF) that will expand the distribution of the Company's award-winning portfolio of medical marijuana

Flow Capital Announces a C$15.0M Investment in Common Wealth

(TSX-V:FW), TORONTO, ON, July 31, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” or the “Company”) is pleased to announce a C$15.0 million senior secured note in Common Wealth Pension Services Inc. (dba “Common Wealth”), a SaaS company serving the Canadian group retirement market, with a first tranche advance of C$4.0 million.

Effective Date of Consolidation of Shares

(CNSX:URM),(CNSX:URM.CN),(Boerse Frankfurt – Freiverkehr:IOR),(Pinksheets:FAUMF),(PinkSheets:FAUMF), Vancouver, British Columbia , July 31, 2025 (GLOBE NEWSWIRE) — First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (the “Company”) announces, further to its news release of July 21, 2025 and effective August 6, 2025, the Company will consolidate the common shares in the capital of the Company (the

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

(NASDAQ:AVXL), New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) 'time saved' by early-start ADAS-Cog13 difference: âˆ'5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P < 0.0001) Restoring impaired autophagy as early event, preceding amyloid-beta and tau Oral presentation at the Alzheimer's Association International Conference (AAIC) 2025 NEW YORK, July 31, 2025

ZenaTech’s ZenaDrone Initiates AUVSI Membership Upgrade, Enabling Leadership on Drone Policy and Strengthening US Defense and Government Engagement

(NASDAQ:ZENA),(Boerse Frankfurt – Freiverkehr:49Q),(BMV:ZENA), VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces its drone subsidiary ZenaDrone has initiated upgrading its membership

Scroll to Top